Mark E. Bunnage, EVP, Chief Scientific Officer: Vertex Pharmaceuticals VRTX Sell · Filed 02/26

Trade details

Type: Insider sale
Amount: $301,537
Shares · price: 620 sh · $486.35 a share
Held after: 7,284 sh
Stock: Vertex Pharmaceuticals VRTX
Person: Mark E. BunnageEVP, Chief Scientific Officer
Trade date: 26/02/25
Filed: 26/02/26
Days to filing: 1 days

Sold 7.8% of holdings

Share of holding sold: 7.8%

Vertex Pharmaceuticals trades, last 26 weeks

What else happened in Vertex Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 01/26~03/27

Mark E. Bunnage's recent trades

Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$15K
33 sh
$15K
Filed 05/19
Traded 05/15
Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$15K
33 sh
$15K
Filed 05/15
Traded 05/15
Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$301.5K
620 sh
$301.5K
Filed 02/25
Traded 02/25
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$1.2M
2,437 sh
$1.2M
Filed 02/19
Traded 02/17
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$559.9K
1,182 sh
$559.9K
Filed 02/19
Traded 02/18